Ultra rapid lispro (URLi) is a novel formulation of insulin lispro designed to more closely
match the physiological insulin response to a meal, with the aim of improving postprandial …

Aims To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults
with type 1 diabetes in a 26‐week, treat‐to‐target, phase 3 trial. Materials and methods After …

URLi is a novel prandial insulin lispro formulation developed to more closely match
physiological insulin secretion. This phase 3, multicenter, treat-to-target, 26-week trial …

URLi is a novel prandial insulin lispro formulation developed to more closely match
physiological insulin secretion. This phase 3, 26-week trial evaluated the efficacy and safety …

Aims To investigate the efficacy and safety of ultra‐rapid lispro (URLi) versus insulin lispro in
predominantly Chinese patients with type 1 diabetes (T1D) in a prospective, randomized …

Abstract Introduction The PRONTO-T1D study, which evaluated the efficacy and safety of
ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary …

Abstract Introduction Ultra-rapid lispro (URLi) is a new prandial insulin lispro formulation. In
the PRONTO-T2D study, URLi, in a basal-bolus regimen with glargine or degludec, was non …

Background: This study evaluated glucose control by continuous glucose monitoring (CGM)
during treatment with ultra-rapid lispro (URLi) or lispro used in combination with insulin …

OBJECTIVE To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in
patients with type 2 diabetes on a basal-bolus insulin regimen. RESEARCH DESIGN AND …

Introduction We evaluated the efficacy and safety of ultra-rapid lispro (URLi) in comparison
to lispro in a subgroup analysis of Japanese adults with type 1 diabetes mellitus from the …